Geode Capital Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-14,335
| Closed | -$123K | – | 4639 |
|
|
2024
Q1 | $123K | Buy |
14,335
+3,896
| +37% | +$18.6K | ﹤0.01% | 4098 |
|
|
2023
Q4 | $36.6K | Sell |
10,439
-222
| -2% | -$781 | ﹤0.01% | 4421 |
|
|
2023
Q3 | $38K | Buy |
10,661
+2,870
| +37% | +$15.4K | ﹤0.01% | 4486 |
|
|
2023
Q2 | $45.3K | Hold |
7,791
| – | – | ﹤0.01% | 4524 |
|
|
2023
Q1 | $295K | Hold |
7,791
| – | – | ﹤0.01% | 3867 |
|
|
2022
Q4 | $232K | Sell |
7,791
-17
| -0.2% | -$514 | ﹤0.01% | 4023 |
|
|
2022
Q3 | $260K | Hold |
7,808
| – | – | ﹤0.01% | 4053 |
|
|
2022
Q2 | $312K | Buy |
7,808
+155
| +2% | +$6K | ﹤0.01% | 4012 |
|
|
2022
Q1 | $402K | Buy |
7,653
+457
| +6% | +$23K | ﹤0.01% | 4056 |
|
|
2021
Q4 | $398K | Sell |
7,196
-91
| -1% | -$5.81K | ﹤0.01% | 4161 |
|
|
2021
Q3 | $564K | Buy |
7,287
+396
| +6% | +$33.5K | ﹤0.01% | 3974 |
|
|
2021
Q2 | $894K | Buy |
6,891
+1,643
| +31% | +$227K | ﹤0.01% | 3661 |
|
|
2021
Q1 | $863K | Buy |
5,248
+1,814
| +53% | +$349K | ﹤0.01% | 3614 |
|
|
2020
Q4 | $803K | Buy |
+3,434
| New | +$478K | ﹤0.01% | 3432 |
|
|
2019
Q4 | – | Sell |
-488
| Closed | -$43K | – | 4237 |
|
|
2019
Q3 | $43K | Hold |
488
| – | – | ﹤0.01% | 4082 |
|
|
2019
Q2 | $66K | Buy |
488
+203
| +71% | +$32.1K | ﹤0.01% | 4039 |
|
|
2019
Q1 | $78K | Hold |
285
| – | – | ﹤0.01% | 3943 |
|
|
2018
Q4 | $35K | Hold |
285
| – | – | ﹤0.01% | 4043 |
|
|
2018
Q3 | $116K | Hold |
285
| – | – | ﹤0.01% | 3900 |
|
|
2018
Q2 | $153K | Buy |
285
+150
| +111% | +$79.8K | ﹤0.01% | 3784 |
|
|
2018
Q1 | $62K | Hold |
135
| – | – | ﹤0.01% | 3922 |
|
|
2017
Q4 | $90K | Hold |
135
| – | – | ﹤0.01% | 3843 |
|
|
2017
Q3 | $85K | Hold |
135
| – | – | ﹤0.01% | 3850 |
|
|
2017
Q2 | $64K | Sell |
135
-9
| -6% | -$5.49K | ﹤0.01% | 3918 |
|
|
2017
Q1 | $107K | Buy |
144
+2
| +1% | +$1.79K | ﹤0.01% | 3818 |
|
|
2016
Q4 | $139K | Buy |
142
+20
| +16% | +$22.9K | ﹤0.01% | 3716 |
|
|
2016
Q3 | $165K | Hold |
122
| – | – | ﹤0.01% | 3663 |
|
|
2016
Q2 | $106K | Hold |
122
| – | – | ﹤0.01% | 3787 |
|
|
2016
Q1 | $170 | Hold |
122
| – | – | ﹤0.01% | 3684 |
|
|
2015
Q4 | $225K | Buy |
122
+24
| +24% | +$48K | ﹤0.01% | 3637 |
|
|
2015
Q3 | $191K | Buy |
98
+6
| +7% | +$14K | ﹤0.01% | 3695 |
|
|
2015
Q2 | $208K | Buy |
+92
| New | +$216K | ﹤0.01% | 3574 |
|
Other funds holding TCON
Geode Capital Management's TCON Position: Q2 2024 in Review
Geode Capital Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 14,335 shares — an estimated $123K sold.
Geode Capital Management first reported a position in TCON in Q2 2015 and held it in 32 quarters. The position peaked at $894K in Q2 2021. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Geode Capital Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Geode Capital Management sold 14,335 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $123K.
- Geode Capital Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2015 and held it in 32 quarters.
- Geode Capital Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $894K in Q2 2021.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.